PerspectiveDRUG DESIGN

Clinical chemoproteomics—Opportunities and obstacles

+ See all authors and affiliations

Science Translational Medicine  19 Apr 2017:
Vol. 9, Issue 386, eaaf7951
DOI: 10.1126/scitranslmed.aaf7951

Article Information

vol. 9 no. 386

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication 31 March 2016.
  • Accepted for publication 6 March 2017.

Author Information

  1. Lyn H. Jones1,* and
  2. Hendrik Neubert2
  1. 1Medicine Design, Pfizer, 610 Main Street, Cambridge, MA 02139, USA.
  2. 2Biomedicine Design, Pfizer, Andover, MA 01810, USA.
  1. *Corresponding author. Email: lynhowardjones{at}gmail.com

AltMetrics

Article usage

AbstractFullPDF
Apr 20172876132262

Related Content